Eli Lilly, a pharmaceutical company, agreed to acquire Radionetics, a biotechnology company discovering and developing novel small molecule G protein coupled receptor, for $1bn. "We are fortunate to have entered into an agreement with Lilly given its global development capability, oncology expertise, and the radiopharmaceutical experience and capabilities Lilly is building following the acquisition of POINT Biopharma," Paul Grayson, Radionetics Oncology CEO.